Abiomed Inc.
Most Recent
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Exploring Abiomed’s Latest Performance Trends
In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.
Why Abiomed Has Risen 103.6% YTD
Abiomed (ABMD) has reported a 103.6% YTD rise in the stock, from $192.49 on January 2, 2018, to $377.49 on September 7, 2018.
What Analysts Expect for Abiomed
Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.
How Abiomed’s Revenue Trended in the First Quarter
Abiomed’s top line increased by ~35.9% to ~$180.0 million in Q1 2019.
Do Abiomed’s Valuations Look Attractive?
Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.
S&P 500’s Top Losses: Nielsen Holdings and Facebook
Nielsen Holdings, which is a global information, data, and measurement company, was the S&P 500’s top loss on July 26.
What Analysts Think of BioLife Solutions Stock
BioLife Solutions (BLFS) has risen from a low of $10.90 on June 28 to a high of $17.60 on July 3. BLFS closed at $16.70 on July 3.
Impella Devices Witnessed Robust Demand in Fiscal 2018
In the United States, Abiomed reported Impella heart pump sales of ~$146.2 million in the fiscal fourth quarter of 2018.
Analyzing ABMD, BR, and TFX Stocks
Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively.
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.
Total Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).
18 Earnings Reports We’re Watching Closely Next Week
Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]
What Analysts Recommend for Edwards Lifesciences
Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.
Analyzing Edwards Lifesciences’ Recent Acquisitions
In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.
Why Abiomed’s Product Pipeline Looks Promising
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.
What Analysts Recommend for Abiomed and Peers in February 2018
Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating.
Exploring Merit Medical Systems’ Business Segments
In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.
Merit Medical Systems: Analysts’ Ratings in February 2018
Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.
Analysts’ Ratings for NxStage Medical and Peers in February 2018
NxStage Medical sells its products and offers services in three markets: home, critical care, and in-center.
Edwards Lifesciences: Analyst Recommendations in November
In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.
HVAD Expected to Expand Medtronic’s Presence in LVAD Segment
On September 27, 2017, the FDA approved Medtronic’s HVAD (HeartWare ventricular assist device) system as a destination therapy for advanced heart failure patients.
Medtronic Focused on Efficacy and Safety of LVAD Offerings
Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.
Heartware Acquisition Boosts MDT’s Position in Ventricular Assist Device Segment
The ~$1.1 billion Heartware International deal has strengthened Medtronic’s position in the VAD market, which was estimated to be worth $800 million in 2016.
Abiomed Is Focused on Expanding Impella’s International Presence
In the last quarter of fiscal 2017, Abiomed (ABMD) reported international market revenue of nearly $10.7 million, a year-over-year (or YoY) rise of ~58%.
Abiomed Aims to Expand Impella RP’s Penetration Going Forward
In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.
Understanding Abiomed’s Changing Payment Structure Plans for Impella
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
Where Abiomed Plans to Expand Impella CP’s Label
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.
Why Abiomed Expects to Benefit from Impella in Cardiogenic Shock
On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device.
Behind Abiomed’s Plans to Create a Greater Awareness of Impella
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.
Abiomed Expects to Expand Its Presence in This Space
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
Abiomed in 2017: The Analysts’ View
For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.
Inside IHI’s Mid-Caps: Masimo Shares Rise on Better 1Q16
When Masimo announced its 1Q16 earnings, it closed at $45.75 and was trading above its 20-day moving average. On a year-to-date basis, the stock has risen 10.2%.
Thoratec Acquisition: The Impact on St. Jude’s Growth Potential
On October 8, 2015, St. Jude Medical (STJ) completed the acquisition of Thoratec for $3.3 billion in net cash consideration. It’s St. Jude’s largest acquisition ever.
St. Jude’s Heart Failure Segment: Performance and Opportunities
St. Jude Medical’s (STJ) heart failure therapy area generated sales of $4 billion and witnessed mid-single-digit growth in 2015.
The iShares US Medical Devices ETF (IHI) Has Put Nothing under the Tree in December—Yet
The iShares US Medical Devices ETF (IHI) rose by 1.15% on December 15, closing at $122.32, 2% higher than its 100-day moving average price of $119.8.
Nuvasive Traded above Its 100-Day Moving Average
Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.